CAJ | 학술논문

目的应用变形配准功能评价肺癌患者放疗计划中正常组织和危及器官的累加剂量,并与经验计算剂量累加法进行比较.方法回顾性分析10例肺癌患者,放疗前制定了三维适形或调强治疗计划,放疗过程中重新行CT模拟,并重新设计相同的治疗计划.采用Mimvista软件,运用变形配准,分别在2次CT图像上进行剂量累加.采用经验计算剂量累加法,计算2次放疗计划的正常组织和危及器官的累加剂量,分别对两种方法的双侧肺组织、心脏及脊髓的受照剂量体积以及平均剂量等参数,进行比较.结果定位和复位图像采用相同的计划方式时,两种方法所得正常组织和危及器官的累积受照体积和剂量等参数差异无统计学意义,仅右肺的平均剂量除外(t=2.98,P＜0.05).结论变形配准法可以准确评价肺癌患者多次放疗计划中正常组织和危及器官的累加剂量.肺癌患者的靶区变化不大并且采用相同的计划方式时,应用经验计算剂量累加法,可粗略评价肺和心脏等正常组织和危及器官的剂量体积.
목적 응용변형배준공능평개폐암환자방료계화중정상조직화위급기관적루가제량,병여경험계산제량루가법진행비교.방법 회고성분석10례폐암환자,방료전제정료삼유괄형혹조강치료계화,방료과정중중신행CT모의,병중신설계상동적치료계화.채용Mimvista연건,운용변형배준,분별재2차CT도상상진행제량루가.채용경험계산제량루가법,계산2차방료계화적정상조직화위급기관적루가제량,분별대량충방법적쌍측폐조직、심장급척수적수조제량체적이급평균제량등삼수,진행비교.결과 정위화복위도상채용상동적계화방식시,량충방법소득정상조직화위급기관적루적수조체적화제량등삼수차이무통계학의의,부우폐적평균제량제외(t=2.98,P＜0.05).결론 변형배준법가이준학평개폐암환자다차방료계화중정상조직화위급기관적루가제량.폐암환자적파구변화불대병차채용상동적계화방식시,응용경험계산제량루가법,가조략평개폐화심장등정상조직화위급기관적제량체적.
Objective To evaluate the accumulated doses to normal tissues and organs at risks (OARs) of patients with lung cancer in radiotherapy plans by using the deformable registration method,and make comparison with the empirical calculation method.Methods Ten patients with lung cancer were analyzed retrospectively.3D-CRT or IMRT plans were designed before treatment. CT to simulator was rescanned and the same treatment plan was redesigned during radiotherapy. Based on the deformable registration method,the Mimvista software was used to calculate the accumulated doses to normal tissues and OARs in two CT images respectively.The empirical estimation algorithm was calculated by the linear relationship between the fractions and the total prescribed dose.Results The target coverage of patients had no significant difference in two plans.There were no significant differences in all the dose volume parameters for normal tissues and OARs,except the mean dose to right lung( t =2.98,P ＜ 0.05 ) when the the same plan was conducted in position-setting and reposition CT images.Conclusions The empirical estimation for the accumulated dose could be used to evaluate the dose and volume parameters for normal tissues and OARs in lung cancer by the same plan.